Literature DB >> 209806

Response kinetics of host and experimental solid tumour after adriamycin.

H A Hopkins, W B Looney, K Teja, A S Hobson, M S MacLeod.   

Abstract

The effects of adriamycin (Adr) on the solid-tumour model, hepatoma 3924A, and on critical organs of the host, were determined at intervals after single injections of 60 mg/m2 of the agent. A reduced rate of tumour growth was evident 4 days after treatment, continued to Day 11, and then returned to rates comparable to control values. On Day 11 tumour volumes of treated animals were 38% of control. During the period of reduced growth, 3H-TdR incorporation into tumour DNA and percentage labelled tumour cells were less than control values. DNA concentration in tumour was not affected by drug treatment, which differs from observations made in other studies employing 5-fluorouracil (FU). No evidence of significantly increased necrosis or fibrosis of the tumour was found after Adr. The Adr treatment caused loss of 60% of the tibial marrow by Day 4, as measured by total DNA content. Marrow DNA recovered to control levels between Days 7 and 11. Incorporation of 3H-TdR into heart DNA was reduced more than 40% during the first week after Adr treatment; enhanced incorporation was observed on Day 11, and control levels were attained by Day 17. No significant pathological evidence of cardiac toxicity was found 2-21 days after Adr but degeneration of myocardial cells and oedema was prominent at 14 weeks.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 209806      PMCID: PMC2009638          DOI: 10.1038/bjc.1978.146

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

2.  Synchronization of host and tumor responses for sequential therapy in experimental solid tumors.

Authors:  H A Hopkins; W B Looney
Journal:  Antibiot Chemother (1971)       Date:  1978

3.  The interaction between radiation and adriamycin damage in mammalian cells.

Authors:  J A Belli; A J Piro
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

4.  Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats.

Authors:  F P Mettler; D M Young; J M Ward
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

5.  Cardiotoxicity of adriamycin and related anthracyclines.

Authors:  L Lenaz; J A Page
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

6.  Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy.

Authors:  W B Looney; J S Trefil; H A Hopkins; C J Kovacs; R Ritenour; J G Schaffner
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

7.  The effect of adriamycin on cell cycle progression and DNA replication in chinese hamster ovary cells.

Authors:  J M Clarkson; R M Humphrey
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

8.  Differential recovery of intestine, bone marrow, and thymus of rats with solid tumors following 5-fluorouracil administration.

Authors:  H A Hopkins; C J Kovacs; W B Looney; J A Wakefield
Journal:  Cancer Biochem Biophys       Date:  1976

9.  Cell proliferation in organs of rats bearing hepatoma 3924A: effects of X-rays of surgery.

Authors:  H A Hopkins; C J Kovacs; W B Looney; J A Wakefield; A S Hobson; H P Morris
Journal:  Cancer Biochem Biophys       Date:  1977

10.  Molecular interactions between adriamycin and x-ray damage in mammalian tumor cells.

Authors:  J E Byfield; Y C Lee; L Tu
Journal:  Int J Cancer       Date:  1977-02-15       Impact factor: 7.396

View more
  1 in total

1.  In vivo tumour-cell proliferation after adriamycin treatment.

Authors:  R Rowley; H A Hopkins; W B Looney
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.